We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use °Ç¸ç³Ô¹Ï, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Help improve °Ç¸ç³Ô¹Ï
The new inhalers use a next-generation propellant designed to reduce environmental impact while maintaining the same established treatment.
As with any medicinal product, the MHRA will keep the safety and effectiveness of nerandomilast under close review.  
Merkel cell carcinoma (MCC) is a rare and aggressive type of skin cancer that develops from Merkel cells, specialised neuroendocrine cells found in the top layer of the skin.
The semaglutide injection has been approved to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis.
MHRA CEO argues that for the UK’s long-term health and prosperity, regulation should help lead, rather than follow, innovation
As with any medicinal product, the MHRA will keep the safety and effectiveness of the intravesical delivery system containing gemcitabine under close review.  
As with any medicine, the MHRA will keep the safety and effectiveness of the adrenaline nasal spray under close review.  
Having met the MHRA’s rigorous standards of safety, quality and effectiveness, the semaglutide tablet has been approved in the UK for weight loss and weight management.
As with all medicines, the MHRA will keep the safety and effectiveness of Nipolcalimab under close review.
The adjuvanted trivalent influenza vaccine works by stimulating the immune system to produce its own protection against flu.
Resmetirom is used in adults who have experienced inflammation and cell damage, resulting in scarring.
As with any medicine, the MHRA will keep the safety and effectiveness of rilzabrutinib under close review.
The MHRA launches public consultation on new framework that could lead to earlier licensing for therapies for up to 3.5 million people in the UK.
As with any medicine, the MHRA will keep the safety and effectiveness of Vyjuvek under close review.
MHRA approves donidalorsen (Dawnzera) for the treatment of hereditary angioedema
As with all medicines, we will continue to closely monitor the safety and effectiveness of linerixibat as it is used more widely.
As with any medicine, the MHRA will keep the safety and effectiveness of Enflonsia under close review.
As with any medicine, the MHRA will keep the safety and effectiveness of sevabertinib under close review.
New pathway set to synchronise licensing and value assessment decisions
As with any medicine, the MHRA will keep the safety and effectiveness of deuruxolitinib under close review.
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve °Ç¸ç³Ô¹Ï, we’d like to know more about your visit today. .